Okuda M, Teramoto T, Yoshida H, Sato K, Ushijima Y, Uematsu Y
Gan To Kagaku Ryoho. 1982 Sep;9(9):1580-8.
1.5 g/day of FT-207 suppository was administered for two weeks prior to operation to twenty patients with large bowel carcinoma of familiar poliposis coli. The level of FT-207 and 5-FU in serum, lymph node, tumor and normal colonic mucosa were determined by bioassay. The levels of FT-207 in the rectum, sigmoid colon and tumor were higher than that in serum. The levels of 5-FU in the rectum, sigmoid colon, tumor and lymph node were also higher than that in serum. The levels of FT-207 and 5-FU in carcinoma of the rectum was higher than those in serum. Compared with the level in normal rectal mucosa, only the level of 5-FU in rectal carcinoma was higher. From the histological point of view, the highest levels of FT-207 and 5-FU was observed in well-differentiated adenocarcinoma. There was no side effect experienced in our series, therefore, FT-207 suppository seems to be one of the safe promising preoperative chemotherapies.
术前两周，对20例家族性结肠息肉病的大肠癌患者，每天给予1.5克FT - 207栓剂。采用生物测定法测定血清、淋巴结、肿瘤及正常结肠黏膜中FT - 207和5 - FU的水平。直肠、乙状结肠和肿瘤中FT - 207的水平高于血清中的水平。直肠、乙状结肠、肿瘤和淋巴结中5 - FU的水平也高于血清中的水平。直肠癌中FT - 207和5 - FU的水平高于血清中的水平。与正常直肠黏膜中的水平相比，仅直肠癌中5 - FU的水平较高。从组织学角度来看，在高分化腺癌中观察到FT - 207和5 - FU的水平最高。在我们的系列研究中未观察到副作用，因此，FT - 207栓剂似乎是一种安全且有前景的术前化疗方法之一。
